Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target lowered by Piper Sandler from $19.00 to $10.00 in a research note released on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. TVTX has been the subject of several other research reports. JPMorgan Chase & Co. started coverage on Travere […]